Odense, Denmark – Over the past two decades, immunotherapy – utilizing the body’s own immune system to combat illness – has emerged as a groundbreaking treatment for various types of cancer. The body’s own T-cells possess a remarkable capacity to identify and fight a wide range of cancers. Regrettably, cancer...
treatment News
MDUK is delighted to bring you the news that a highly complex, innovative gene therapy is to become available on the NHS in England for the treatment of spinal muscular atrophy (SMA) Type 1. Babies born with SMA Type 1, the most common form of the condition, are unable to...
Garden City, NY — ProPhase Labs Inc. (NASDAQ: PRPH), a next-generation biotech, genomics, and diagnostics company, today reported its progress on the commercialization of its breakthrough BE-Smart test for esophageal cancer. The Company is aiming for commercial launch in the second half of 2024. Ted Karkus, CEO of ProPhase Labs,...
LEIDEN, Netherlands & CAMBRIDGE, Mass. – ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced results from a planned analysis of its Phase 1/2 Stellar trial of QR-421a in adults with Usher syndrome and...
WELLESLEY HILLS, Mass. — Joseph F. Finn, Jr., C.P.A. (“Finn”) announced today that Prospect Therapeutics has focused on developing GCS-100 for treatment of three blood-borne cancers: chronic lymphocytic leukemia (“CLL”), multiple myeloma (“MM”) and diffuse large B cell lymphoma (“DLBCL”). In clinical studies, GCS-100 has demonstrated activity as a single...
HERLEV, Denmark — A leading Danish cancer hospital has treated its first patient using RapidArc(R) radiotherapy after installing eight advanced radiotherapy treatment machines from Varian Medical Systems (NYSE: VAR) of Palo Alto, California. Herlev Hospital, to the north-west of Copenhagen, delivered the fast and efficient RapidArc treatment to a prostate...
A new prostate cancer risk assessment test, developed by a UCSF team, gives patients and their doctors a better way of gauging long-term risks and pinpointing high risk cases. According to UCSF study findings, published this week, the test proved accurate in predicting bone metastasis, prostate cancer-specific mortality, and all-cause...
KVISTGARD, Denmark — Detailed data from a randomized Phase 2 study with PROSTVAC(TM) were presented at the ASCO Annual Meeting in Orlando. The presentation was made by Philip Kantoff MD, Professor of Medicine, Harvard Medical School, and the Dana-Farber Cancer Institute who is also the principal investigator of the study....
NEWARK, Calif. – Protagonist Therapeutics (Nasdaq:PTGX) (“Protagonist” or “the Company”) today announced updated results from the ongoing Phase 2 study of rusfertide, an investigational new drug being evaluated for the treatment of polycythemia vera (PV). “This data set cumulatively builds on previously presented scientific evidence demonstrating rusfertide’s potential as the first-in-class,...
NEWARK, Calif. – Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) (Nasdaq: PTGX), today announced the completion of enrollment for the Company’s Phase 2 study of rusfertide (PTG-300) in polycythemia vera (“PV”). Enrollment easily exceeded the targeted 50 evaluable patients for the study. Those patients eligible for enrollment, but unable to...